Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts.

Published on Nov 1, 2019in European Urology17.947
· DOI :10.1016/J.EURURO.2019.07.041
Frank-Jan H. Drost6
Estimated H-index: 6
(Erasmus University Medical Center),
Daan Nieboer28
Estimated H-index: 28
(Erasmus University Medical Center)
+ 73 AuthorsJozien Helleman19
Estimated H-index: 19
Sources
Abstract
Abstract Background Men with prostate cancer (PCa) on active surveillance (AS) are followed through regular prostate biopsies, a burdensome and often unnecessary intervention, not without risks. Identifying men with at a low risk of disease reclassification may help reduce the number of biopsies. Objective To assess the external validity of two Canary Prostate Active Surveillance Study Risk Calculators (PASS-RCs), which estimate the probability of reclassification (Gleason grade ≥7 with or without >34% of biopsy cores positive for PCa) on a surveillance biopsy, using a mix of months since last biopsy, age, body mass index, prostate-specific antigen, prostate volume, number of prior negative biopsies, and percentage (or ratio) of positive cores on last biopsy. Design, setting, and participants We used data up to November 2017 from the Movember Foundation’s Global Action Plan (GAP3) consortium, a global collaboration between AS studies. Outcome measurements and statistical analysis External validity of the PASS-RCs for estimating reclassification on biopsy was assessed by calibration, discrimination, and decision curve analyses. Results and limitations Five validation cohorts (Prostate Cancer Research International: Active Surveillance, Johns Hopkins, Toronto, Memorial Sloan Kettering Cancer Center, and University of California San Francisco), comprising 5105 men on AS, were eligible for analysis. The individual cohorts comprised 429–2416 men, with a median follow-up between 36 and 84 mo, in both community and academic practices mainly from western countries. Abilities of the PASS-RCs to discriminate between men with and without reclassification on biopsy were reasonably good (area under the receiver operating characteristic curve values 0.68 and 0.65). The PASS-RCs were moderately well calibrated, and had a greater net benefit than most default strategies between a predicted 10% and 30% risk of reclassification. Conclusions Both PASS-RCs improved the balance between detecting reclassification and performing surveillance biopsies by reducing unnecessary biopsies. Recalibration to the local setting will increase their clinical usefulness and is therefore required before implementation. Patient summary Unnecessary prostate biopsies while on active surveillance (AS) should be avoided as much as possible. The ability of two calculators to selectively identify men at risk of progression was tested in a large cohort of men with low-risk prostate cancer on AS. The calculators were able to prevent unnecessary biopsies in some men. Usefulness of the calculators can be increased by adjusting them to the characteristics of the population of the clinic in which the calculators will be used.
📖 Papers frequently viewed together
4 Citations
77 Citations
References32
Newest
#1Ben Van Calster (Katholieke Universiteit Leuven)H-Index: 48
#2Laure Wynants (Katholieke Universiteit Leuven)H-Index: 20
Last. Ewout W. Steyerberg (EUR: Erasmus University Rotterdam)H-Index: 157
view all 8 authors...
Abstract Context Urologists regularly develop clinical risk prediction models to support clinical decisions. In contrast to traditional performance measures, decision curve analysis (DCA) can assess the utility of models for decision making. DCA plots net benefit (NB) at a range of clinically reasonable risk thresholds. Objective To provide recommendations on interpreting and reporting DCA when evaluating prediction models. Evidence acquisition We informally reviewed the urological literature to...
119 CitationsSource
#1Sophie Bruinsma (EUR: Erasmus University Rotterdam)H-Index: 13
#2Liying Zhang (Sunnybrook Health Sciences Centre)H-Index: 2
Last. Mieke Van Hemelrijck ('KCL': King's College London)H-Index: 36
view all 7 authors...
OBJECTIVES: The Movember Foundation launched the Global Action Plan Prostate Cancer Active Surveillance (GAP3) initiative to create a global consensus on the selection and monitoring of men with low‐risk prostate cancer (PCa) on active surveillance (AS). The aim of this study is to present data on inclusion and follow‐up for AS in this unique global AS database. PATIENTS AND METHODS: Between 2014 and 2016, the database was created by combining patient data from 25 established AS cohorts worldwid...
30 CitationsSource
#1Frank-Jan H. Drost (Erasmus University Medical Center)H-Index: 6
#2Antti Rannikko (UH: University of Helsinki)H-Index: 30
Last. Monique J. Roobol (Erasmus University Medical Center)H-Index: 76
view all 9 authors...
Background: Active surveillance (AS) for low-risk prostate cancer (PCa) appears to provide excellent longterm PCa-specific and overall survival. The choice for AS as initial treatment is mainly based on avoiding side effects from invasive treatment; but AS entails regular check-ups and the possibility of still having to switch or deciding to switch to invasive treatment. Here, we assessed the long-term follow-up data from AS in real life clinical practices. Methods: Data from the first 500 men, ...
14 CitationsSource
#1Stacy Loeb (NYU: New York University)H-Index: 68
#2Jeffrey J. Tosoian (Johns Hopkins University)H-Index: 29
The use of active surveillance (AS) is increasing for favorable-risk prostate cancer. However, there remain challenges in patient selection for AS, due to the limitations of current clinical staging. In addition, monitoring protocols relying on serial biopsies is invasive and presents risks such as infection. For these reasons, there is substantial interest in identifying markers that can be used to improve AS selection and monitoring. In this article, we review the evidence on serum, urine and ...
8 CitationsSource
#1Monique J. RoobolH-Index: 76
#2J. VerbeekH-Index: 1
Last. Mark FrydenbergH-Index: 47
view all 11 authors...
1 CitationsSource
#2José Rubio-BrionesH-Index: 15
Last. Juan Soto-VillalbaH-Index: 2
view all 14 authors...
// Angel Borque-Fernando 1, * , Jose Rubio-Briones 2, * , Luis Mariano Esteban 3 , Argimiro Collado-Serra 2 , Yoni Pallas-Costa 4 , Pedro Angel Lopez-Gonzalez 5 , Jorge Huguet-Perez 6 , Jose Ignacio Sanz-Velez 7 , Jesus Manuel Gil-Fabra 1 , Enrique Gomez-Gomez 8 , Cristina Quicios-Dorado 9 , Lluis Fumado 10 , Sara Martinez-Breijo 11 and Juan Soto-Villalba 12 , on behalf of the PIEM Active Surveillance Study Group 1 Department of Urology, Hospital Universitario Miguel Servet, IIS-Aragon, Zaragoza...
4 CitationsSource
#1Geraldine N. Tran (UCSF: University of California, San Francisco)H-Index: 4
#2Michael S. Leapman (UCSF: University of California, San Francisco)H-Index: 16
Last. Peter R. Carroll (UCSF: University of California, San Francisco)H-Index: 141
view all 7 authors...
Abstract Background Fusion biopsy using multiparametric magnetic resonance imaging (MRI) and transrectal ultrasound has demonstrated favorable detection rates of high-grade prostate cancer (PCa) among previously undiagnosed men. However, the diagnostic yield among men with active surveillance (AS) remains undefined. Objective To determine the utility of MRI-ultrasound fusion biopsy during AS by reporting rates of PCa upgrading and comparing findings with systematic biopsy. Design, setting, and p...
61 CitationsSource
#1Amy N. Luckenbaugh (UM: University of Michigan)H-Index: 7
#2Gregory B. Auffenberg (UM: University of Michigan)H-Index: 7
Last. David C. Miller (UM: University of Michigan)H-Index: 54
view all 7 authors...
Purpose: We examined the frequency of followup prostate specific antigen testing and prostate biopsy among men treated with active surveillance in the academic and community urology practices comprising MUSIC (Michigan Urological Surgery Improvement Collaborative).Materials and Methods: MUSIC is a consortium of 42 practices that maintains a prospective clinical registry with validated clinical data on all patients diagnosed with prostate cancer at participating sites. We identified all patients ...
29 CitationsSource
#1Marco Borghesi (UNIBO: University of Bologna)H-Index: 26
#2Hashim U. Ahmed (UCL: University College London)H-Index: 62
Last. Stacy Loeb (NYU: New York University)H-Index: 68
view all 8 authors...
Abstract Context Prostate biopsy (PB) represents the gold standard method to confirm the presence of cancer. In addition to traditional random or systematic approaches, a magnetic resonance imaging (MRI)–guided technique has been introduced recently. Objective To perform a systematic review of complications after transrectal ultrasound (TRUS)–guided, transperineal, and MRI-guided PB. Evidence acquisition We performed a systematic literature search of Web of Science, Embase, and Scopus databases ...
156 CitationsSource
#1Ting Martin Ma (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 9
#2Jeffrey J. Tosoian (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 29
Last. H. Ballentine Carter (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 79
view all 9 authors...
Abstract Background Multiparametric magnetic resonance imaging (mpMRI)/ultrasound fusion biopsy (targeted biopsy or TB) may improve detection of high-grade cancers when compared to systematic biopsy (SB). Objective To assess TB in active surveillance (AS). Design, setting, and participants We retrospectively evaluated SB (12-core sector) and TB among 103 AS men undergoing surveillance biopsy, 54 men undergoing confirmatory biopsy (CB), and 73 men referred for diagnostic biopsy (DB; comparison gr...
60 CitationsSource
Cited By8
Newest
#1Joseba Salguero (Cordoba University)
#2Enrique Gómez-Gómez (Cordoba University)
Last. Maria J. Requena (Cordoba University)H-Index: 12
view all 10 authors...
OBJECTIVE To evaluate the impact of multiparametric magnetic resonance imaging (mpMRI) before confirmatory prostate biopsy in patients under active surveillance (AS). MATERIALS AND METHODS This retrospective study included 170 patients with Gleason grade 6 prostate cancer initially enrolled in an AS program between 2011 and 2019. Prostate mpMRI was performed using a 1.5 tesla (T) magnetic resonance imaging system with a 16-channel phased-array body coil. The protocol included T1-weighted, T2-wei...
Source
#1Colton Walker (UM: University of Michigan)
#2Kathryn A Marchetti (UM: University of Michigan)H-Index: 3
Last. Todd M. Morgan (UM: University of Michigan)H-Index: 49
view all 4 authors...
Introduction Active surveillance (AS) has been widely adopted for the management of men with low-risk prostate cancer. However, there is still a lack of consensus surrounding the optimal approach for monitoring men in AS protocols. While conservative management aims to reduce the burden of invasive testing without compromising oncological safety, inadequate assessment can result in misclassification and unintended over- or undertreatment, leading to increased patient morbidity, cost, and undue r...
Source
#1Jiayin Zheng (Fred Hutchinson Cancer Research Center)H-Index: 6
#1Jiayin Zheng (Fred Hutchinson Cancer Research Center)
Last. Li Hsu (Fred Hutchinson Cancer Research Center)H-Index: 53
view all 3 authors...
Predicting risks of chronic diseases has become increasingly important in clinical practice. When a prediction model is developed in a cohort, there is a great interest to apply the model to other ...
Source
#3Xinge JiH-Index: 8
Last. Michael W. KattanH-Index: 137
view all 11 authors...
Background Signs of disease progression (28%) and conversion to active treatment without evidence of disease progression (13%) are the main reasons for discontinuation of active surveillance (AS) in men with localised prostate cancer (PCa). We aimed to develop a nomogram to predict disease progression in these patients. Methods As a first step in the development of a nomogram, using data from Movembers' GAP3 Consortium (n=14,380), we assessed heterogeneity between centres in terms of risk of dis...
Source
#1Sohail Singh ('KCL': King's College London)H-Index: 3
#2Preeti Sandhu ('KCL': King's College London)H-Index: 1
Last. Oussama Elhage ('KCL': King's College London)H-Index: 16
view all 15 authors...
OBJECTIVE To determine the risk of disease progression and conversion to active treatment following a negative biopsy while on active surveillance (AS) for prostate cancer (PCa). PATIENTS AND METHODS Men on an AS programme at a single tertiary hospital (London, UK) between 2003 and 2018 with confirmed low-intermediate-risk PCa, Gleason Grade Group 30% positive cores, magnetic resonance imaging (MRI) Likert score >3/T3 or PSA level of >20 ng/mL. Conversion to treatment included radical or hormona...
Source
#2Jenna E. FongH-Index: 1
Last. Mark BuzzaH-Index: 14
view all 15 authors...
Prostate cancer is a heterogeneous cancer with widely varying levels of morbidity and mortality. Approaches to prostate cancer screening, diagnosis, surveillance, treatment and management differ around the world. To identify the highest priority research needs across the prostate cancer biomedical research domain, Movember conducted a landscape analysis with the aim of maximizing the effect of future research investment through global collaborative efforts and partnerships. A global Landscape An...
3 CitationsSource
Last. Hsu Li (Fred Hutchinson Cancer Research Center)
view all 3 authors...
Predicting risks of chronic diseases has become increasingly important in clinical practice. When a prediction model is developed in a given source cohort, there is often a great interest to apply the model to other cohorts. However, due to potential discrepancy in baseline disease incidences between different cohorts and shifts in patient composition, the risk predicted by the original model often under- or over-estimates the risk in the new cohort. The remedy of such a poorly calibrated predic...
#1Pietro PepeH-Index: 16
Last. Michele PennisiH-Index: 10
view all 4 authors...
BACKGROUND/AIM: To evaluate the diagnostic accuracy of the urinary SelectMDx test in the diagnosis of clinically significant prostate cancer (csPCa) in men enrolled in an active surveillance (AS) protocol. PATIENTS AND METHODS: From July 2015 to July 2018, 125 men with very low-risk PCa were enrolled in the AS protocol; all patients underwent confirmatory transperineal saturation biopsy (SPBx). In the presence of PI-RADS score >/=3, a targeted MRI/TRUS fusion-guided biopsy was added to SPBx. Pos...
5 CitationsSource